If we take some recent examples of other Biotechs on the ASX which have ODD and have or plan for FDA accelerated approval, each have already signed up one or two partnership deals ahead of anticipated approval. That way, all the prepatory work around distribution of the drug occurs in parallel and ready for market launch if accelerated approval comes through. I think it's reasonable to assume that PAA will aim for a similar approach if buyout does not occur. 
If we take some recent examples of other Biotechs on the ASX...
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $99.71M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $66.86K | 327.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27750 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 84999 | 3 |
View Market Depth
| Last trade - 14.42pm 27/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |